Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Stanford tests if droperidol changes how patients like fentanyl during surgery

NCT ID NCT07015528

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study at Stanford University is testing whether the medication droperidol can change how much patients like the feeling of fentanyl, a common painkiller given during procedures. About 130 adults scheduled for surgery will receive either droperidol or a placebo, and then rate their drug liking and sedation levels. The goal is to better understand how these medications affect patient experience, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Droperidol
What this could lead to
If successful, this could help understand how certain medications influence feelings of drug liking in medical settings.
What could go wrong
This is a very early, small study focused on measuring subjective feelings, not treating a disease. Results may not lead to any practical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * American Society of Anesthesiologists (ASA) physical status classification of I, II or III * Candidates who are expected to receive fentanyl up to 3 mcg/kg IBW for their scheduled for surgery or procedure Exclusion Criteria: * Craniofacial abnormalities * Known or suspected difficult intubation or mask ventilation * Known or suspected need for rapid sequence induction and intubation * Allergies or hypersensitivities to droperidol or fentanyl * Clinically significant pulmonary disease, such as chronic obstructive lung disease requiring long-term oxygen therapy, or other conditions that, in the study team's judgment, may increase the risk of severe respiratory depression with opioid administration * History of long QT syndrome * History of Torsades de Pointes * History of psychosis * History of movement disorders e.g. Parkinson's Disease * Past chronic use of anti-psychotics * Current use of droperidol, levodopa, lithium, clozapine, metoclopramide, benzodiazepines * Current use of opioids * History of opiate abuse within the last 3 years * Known or suspected severe chronic pain condition that require use of opiates or limit daily activities * History of pheochromocytoma * History of concomitant prolactin-dependent tumors e.g. prolactinoma, breast cancer * Pregnancy or nursing * Current use of antiemetic medication (i.e., 5HT or dopamine antagonists) * Active seizure disorder * Active mental health disorders resulting in functional impairment * Current use of psychostimulant medications (Adderall) * Current use of CNS depressants (e.g., barbiturates, benzodiazepines) * Severe renal insufficiency (Stage 4 or 5) * Impaired cognitive function * Regular Cannabis use (2+ times per week) * Current history of substance abuse disorder. * Failure to satisfy the investigator of fitness to participate for any other reason

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug liking are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Stanford Hospital

    Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.